Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | F13A1 | P00488 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | TGM1 | P22735 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30599728 | 1.00 | HSD11B1 (0.39) | HSD11B1GPR119HDAC1PARP1MEN1 | |
| SCHEMBL17180207 | 0.83 | GPR119 (0.47) | HSD11B1GPR119HDAC1PARP1MEN1 | |
| SCHEMBL17180205 | 0.83 | GPR119 (0.47) | HSD11B1GPR119HDAC1PARP1MEN1 | |
| SCHEMBL29418497 | 0.78 | GPR119 (0.34) | HSD11B1GPR119RETUSP30 | |
| SCHEMBL25216834 | 0.78 | GPR119 (0.34) | HSD11B1GPR119RETUSP30 | |
| SCHEMBL25214652 | 0.78 | GPR119 (0.48) | GPR119HDAC1 | |
| SCHEMBL29418786 | 0.78 | GPR119 (0.48) | GPR119HDAC1 | |
| SCHEMBL25267705 | 0.76 | NR1H2 (0.41) | GPR119HDAC1MEN1KMT2AUSP30 | |
| SCHEMBL29418548 | 0.76 | NR1H2 (0.41) | GPR119HDAC1MEN1KMT2AUSP30 | |
| SCHEMBL25209734 | 0.76 | GPR119 (0.54) | GPR119MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| CN-116917279-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-4192587-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032019-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BTK, SYK, LYN | HSD11B1 3719/4885GPR119 1014/4885HDAC1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.